+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4661520
  • Drug Pipelines
  • October 2018
  • Region: Global
  • 120 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Access Pharmaceuticals
  • EpicentRx
  • Galera Therapeutics
  • Helsinn Healthcare
  • Indena S.p.A
  • Monar Therapeutics
  • MORE
‘Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of OM in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Oral Mucositis (OM) from 2016 to 2027 segmented by G8 Countries market. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China
Study Period: 2016-2027

Oral Mucositis (OM) - Disease Understanding and Treatment Algorithm

The Oral Mucositis (OM) market report gives the thorough understanding of the Oral Mucositis by including details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Oral Mucositis in the US, Europe, Japan, and China.

Oral Mucositis Epidemiology

The Oral Mucositis (OM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for G8 countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Diagnosed Incident cases, Grade-specific cases, Risk Factor Associated cases), scenario of Oral Mucositis (OM) in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) Japan and China from 2016-2027.

According to this research, total diagnosed incident population of Oral Mucositis (OM) in G8 countries markets was found to be 5,333,193 in 2016.

Oral Mucisitis Drug Chapters

This segment of the Oral Mucositis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic market of G8 Countries is driven majorly by Kepivance, Magic mouthwash, approved mouth rinse (Episil (SP-03), Gelx, Neutrasal, ProThelial, Mucotrol and Painkillers. Detailed chapter for upcoming therapies like EC-18 (Enzychem Lifesciences Corporation), SGX942 (Soligenix Inc.), OPC-12759 (Otsuka Pharmaceuticals), RRx-001 (EpicentRx), AG013 (Oragenics, Inc.), Validive (Monopar Therapeutics), GC4419 (Galera Therapeutics), SAMITAL (Indena S.p.A), Brilacidin (Innovation Pharmaceuticals), Mucomel (Spherium Biomed) and Folotyn and Leucovorin have been covered in the report.

Oral Mucositis Market Outlook

The Oral Mucositis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Oral Mucositis in G8 countries was found to be USD 638.8 Million in 2016, and is expected to increase from 2016-2027.

Oral Mucositis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Oral Mucositis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Oral Mucositis Report Key Strengths
  • 10 Year Forecast
  • G8 Countries Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Oral Mucositis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Oral Mucositis market
  • Organize sales and marketing efforts by identifying the best opportunities for Oral Mucositis market
  • To understand the future market competition in the Oral Mucositis market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Access Pharmaceuticals
  • EpicentRx
  • Galera Therapeutics
  • Helsinn Healthcare
  • Indena S.p.A
  • Monar Therapeutics
  • MORE
1. Key Insights

2. The Report contains:

3. Oral Mucositis Market: Overview at a Glance
3.1. Market Share Distribution of OM in 2017
3.2. Market Share Distribution of OM in 2027

4. Oral Mucositis (OM): Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Etiology
4.4. Risk Factors of Oral Mucositis
4.5. Pathophysiology
4.6. Diagnosis of Oral Mucositis
4.7. Clinical Oral Mucositis Assessment Scales
4.8. World Health Organization (WHO) scale for oral mucositis
4.9. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
4.10. References

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Diagnosed Incident Cases of Oral Mucositis in G8 Countries

6. Country-Specific Epidemiology of Oral Mucositis
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Diagnosed Incident Population of Oral Mucositis in the United States
6.1.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the United States
6.1.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in the United States
6.2. EU5
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Diagnosed Incident Population of Oral Mucositis in Germany
6.3.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Germany
6.3.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Germany
6.4. France
6.4.1. Diagnosed Incident Population of Oral Mucositis in France
6.4.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in France
6.4.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in France
6.5. Italy
6.5.1. Diagnosed Incident Population of Oral Mucositis in Italy
6.5.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Italy
6.5.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Italy
6.6. Spain
6.6.1. Diagnosed Incident Population of Oral Mucositis in Spain
6.6.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Spain
6.6.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Spain
6.7. United Kingdom
6.7.1. Diagnosed Incident Population of Oral Mucositis in the United Kingdom
6.7.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the United Kingdom
6.7.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Diagnosed Incident Population of Oral Mucositis in Japan
6.8.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Japan
6.8.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Japan
6.9. China
6.9.1. Assumptions and Rationale
6.9.2. Diagnosed Incident Population of Oral Mucositis in China
6.9.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in China
6.9.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in China

7. Current Treatment Practices
7.1. Chemotherapy Induced Oral Mucositis Treatment and Prevention
7.2. MASCC/ISOO Guideline Recommendations
7.3. Treatment and Prevention Options for Patients receiving Hematopoietic Stem Cell Transplantation (HSCT)
7.4. Radiotherapy Induced Oral Mucositis Treatment and Prevention
7.5. Treatment of Oral Mucositis and Oral Complications
7.6. UKOMiC (United Kingdom Oral Mucositis in Cancer Group)
7.7. ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

8. Unmet Needs

9. Marketed Drugs
9.1. Key cross competition- Marketed Drugs
9.2. Gelclair: Helsinn Healthcare
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Product Profile
9.3. Caphosol: EUSA Pharma/Canbridge Life Sciences
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. Episil: Solasia Pharma / Camurus AB
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Clinical Development
9.4.4. Product Profile
9.5. MuGard: Access Pharmaceuticals
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Safety and Efficacy
9.5.4. Product Profile
9.6. Kepivance: Swedish Orphan Biovitrum AB
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Clinical Development
9.6.4. Safety and Efficacy
9.6.5. Product Profile

10. Emerging Therapies
10.1. Key cross competition- Emerging Therapies
10.2. Dusquetide: Soligenix Inc.
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. EC-18: Enzychem Lifesciences Corporation
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. Rebamipide: Otsuka Pharmaceutical
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Clinical Development
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.5. RRx-001: EpicentRx
10.5.1. Drug Description
10.5.2. Clinical Development
10.5.3. Product Profile
10.6. AG013: Oragenics Inc
10.6.1. Drug Description
10.6.2. Regulatory Milestones
10.6.3. Clinical Development
10.6.4. Safety and Efficacy
10.6.5. Product Profile
10.7. GC4419: Galera Therapeutics
10.7.1. Drug Description
10.7.2. Regulatory Milestones
10.7.3. Clinical Development
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. SAMITAL: Indena S.p.A
10.8.1. Drug Description
10.8.2. Clinical Development
10.8.3. Safety and Efficacy
10.8.4. Product Profile
10.9. Mucomel: Spherium Biomed
10.9.1. Drug Description
10.9.2. Clinical Development
10.9.3. Safety and Efficacy
10.9.4. Product Profile
10.10. Brilacidin: Innovation Pharmaceuticals
10.10.1. Drug Description
10.10.2. Regulatory Milestones
10.10.3. Clinical Development
10.10.4. Safety and Efficacy
10.10.5. Product Profile
10.11. Validive: Monar Therapeutics
10.11.1. Drug Description
10.11.2. Regulatory Milestones
10.11.3. Clinical Development
10.11.4. Safety and Efficacy
10.11.5. Product Profile
10.12. Folotyn and Leucovorin: Spectrum Pharmaceuticals
10.12.1. Drug Description
10.12.2. Regulatory Milestones
10.12.3. Clinical Development
10.12.4. Product Profile

11. Key Findings

12. Market Size of Oral Mucositis in G8 Countries

13. United States Market Outlook
13.1. United States Market Size
13.1.1. Total Market size of Oral Mucositis
13.1.2. Market Size by Therapies

14. EU5Market Outlook
14.1. Germany Market Size
14.1.1. Total Market size of Oral Mucositis
14.1.2. Market Size by Therapies
14.2. France Market Size
14.2.1. Total Market size of Oral Mucositis
14.2.2. Market Size by Therapies
14.3. Italy Market Size
14.3.1. Total Market size of Oral Mucositis
14.3.2. Market Size by Therapies
14.4. Spain Market Size
14.4.1. Total Market size of Oral Mucositis
14.4.2. Market Size by Therapies
14.5. United Kingdom Market Size
14.5.1. Total Market size of Oral Mucositis
14.5.2. Market Size by Therapies

15. Japan Market Outlook
15.1. Japan Market Size
15.1.1. Total Market size of Oral Mucositis
15.1.2. Market Size by Therapies

16. China Market Outlook
16.1. China Market Size
16.1.1. Total Market size of Oral Mucositis
16.1.2. Market Size by Therapies

17. Market Drivers

18. Market Barriers

19. The Publisher's Capabilities

20. Appendix
20.1. Report Methodology

21. Disclaimer

22. About the Publisher
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Helsinn Healthcare
  • EUSA Pharma/Canbridge Life Sciences
  • Solasia Pharma / Camurus AB
  • Access Pharmaceuticals
  • Swedish Orphan Biovitrum AB
  • Soligenix Inc.
  • Enzychem Lifesciences Corporation
  • Otsuka Pharmaceutical
  • EpicentRx
  • Oragenics Inc
  • Galera Therapeutics
  • Indena S.p.A
  • Innovation Pharmaceuticals
  • Monar Therapeutics
  • Spectrum Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll